{"protocolSection": {"identificationModule": {"nctId": "NCT00758589", "orgStudyIdInfo": {"id": "D9830C00004"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "One Month Dose Response Study of AZD1981 in Asthma Patients Uncontrolled on Inhaled Steroids", "officialTitle": "A Double-blind, Randomised, Parallel Group, Multicentre Phase IIb, Placebo-Controlled, 1 Month Dose Response Study of AZD1981 in Asthma Patients Uncontrolled on Inhaled Steroids", "acronym": "OLIVE"}, "statusModule": {"statusVerifiedDate": "2014-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-09"}, "completionDateStruct": {"date": "2009-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-09-23", "studyFirstSubmitQcDate": "2008-09-24", "studyFirstPostDateStruct": {"date": "2008-09-25", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-07-01", "resultsFirstSubmitQcDate": "2013-10-24", "resultsFirstPostDateStruct": {"date": "2013-12-13", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-01-24", "lastUpdatePostDateStruct": {"date": "2014-02-26", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The primary objective of this study is to evaluate efficacy of AZD1981 in uncontrolled asthmatic patients on maintenance inhaled glucocorticosteroids."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 368, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "AZD1981 50 mg", "type": "EXPERIMENTAL", "description": "AZD1981 50 mg Twice Daily (Bid)", "interventionNames": ["Drug: AZD1981"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo", "interventionNames": ["Drug: Placebo"]}, {"label": "AZD1981 400 mg", "type": "EXPERIMENTAL", "description": "AZD1981 400 mg Twice Daily (Bid)", "interventionNames": ["Drug: AZD1981"]}, {"label": "AZD1981 1000 mg", "type": "EXPERIMENTAL", "description": "AZD1981 1000 mg Twice Daily (Bid)", "interventionNames": ["Drug: AZD1981"]}], "interventions": [{"type": "DRUG", "name": "AZD1981", "description": "Oral tablet, 50 mg twice daily", "armGroupLabels": ["AZD1981 50 mg"]}, {"type": "DRUG", "name": "AZD1981", "description": "Oral tablet, 400 mg twice daily", "armGroupLabels": ["AZD1981 400 mg"]}, {"type": "DRUG", "name": "AZD1981", "description": "Oral tablet, 1000 mg twice daily", "armGroupLabels": ["AZD1981 1000 mg"]}, {"type": "DRUG", "name": "Placebo", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Morning Peak Expiratory Flow (mPEF)", "description": "Mean mPEF during the treatment period (mean of the last 2 weeks of the treatment period)", "timeFrame": "Week 4"}], "secondaryOutcomes": [{"measure": "Evening Peak Expiratory Flow (ePEF)", "description": "Mean ePEF during the treatment period (mean of the last 2 weeks of the treatment period)", "timeFrame": "Week 4"}, {"measure": "Morning Forced Expiratory Volume in 1 Second (mFEV1)", "description": "Mean mFEV1 during the treatment period (mean of the last 2 weeks of the treatment period)", "timeFrame": "Week 4"}, {"measure": "Evening Forced Expiratory Volume in 1 Second (eFEV1)", "description": "Mean eFEV1 during the treatment period (mean of the last 2 weeks of the treatment period)", "timeFrame": "Week 4"}, {"measure": "Total Use of Reliever", "description": "Mean total reliever use during the treatment period (mean of the last 2 weeks of the treatment period)", "timeFrame": "Week 4"}, {"measure": "Night-time Asthma Symptom Score", "description": "Mean night-time asthma symptom score during the treatment period (mean of the last 2 weeks of the treatment period). Scores range from 0 (none) to 3 (bad).", "timeFrame": "Week 4"}, {"measure": "Day-time Asthma Symptom Score", "description": "Mean day-time asthma symptom score during the treatment period (mean of the last 2 weeks of the treatment period). Scores range from 0 (none) to 3 (bad).", "timeFrame": "Week 4"}, {"measure": "Awakenings", "description": "Mean percentage of awakenings due to asthma symptoms during the treatment period (mean of the last 2 weeks of the treatment period)", "timeFrame": "Week 4"}, {"measure": "Asthma Control Day", "description": "Mean percentage of asthma control days during the treatment period (mean of the last 2 weeks of the treatment period). An asthma control day is defined as a symptom-free day with no use of reliever medication during day and night. A symptom-free day is defined as a day and a night with no asthma symptoms and a day and night with no awakenings due to asthma symptoms.", "timeFrame": "Week 4"}, {"measure": "Symptom Free Day", "description": "Mean percentage of symptom free days during the treatment period (mean of the last 2 weeks of the treatment period). A symptom-free day is defined as a day and a night with no asthma symptoms and a day and night with no awakenings due to asthma symptoms.", "timeFrame": "Week 4"}, {"measure": "Reliever Free Day", "description": "Mean percentage of reliever free days during the treatment period (mean of the last 2 weeks of the treatment period). A reliever free day is defined as a day and a night with no use of as-needed medication.", "timeFrame": "Week 4"}, {"measure": "Forced Expiratory Volume in 1 Second (FEV1) at the Clinic", "description": "Mean FEV1 during the treatment period (mean value at Week 4)", "timeFrame": "Week 4"}, {"measure": "Forced Vital Capacity (FVC) at the Clinic", "description": "Mean FVC during the treatment period (mean value at Week 4)", "timeFrame": "Week 4"}, {"measure": "Asthma Control Questionnaire 5 Items (ACQ5)", "description": "Mean ACQ5 score during the treatment period (mean value at Week 4). Scores range from 0 (good) to 6 (poor control).", "timeFrame": "Week 4"}, {"measure": "Adverse Event (AE)", "description": "Number of patients reporting at least one event", "timeFrame": "4 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Six months history of asthma\n* Daily use of inhaled glucocorticosteroids\n* FEV1 40-85% of predicted normal\n* Reversibility; increase in FEV1 more than 12% and 200 mL post-bronchodilator\n\nExclusion Criteria:\n\n* Other clinically relevant disease or disorders\n* History of smoking of more than 10 pack years\n* Respiratory infection within 30 days", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Piotr Kuna", "affiliation": "University of Lodz, Lodz, Poland", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Quilmes", "state": "Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -34.72904, "lon": -58.26374}}, {"facility": "Research Site", "city": "San Miguel de Tucuman", "state": "Tucuman", "country": "Argentina", "geoPoint": {"lat": -26.82414, "lon": -65.2226}}, {"facility": "Research Site", "city": "Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Santa Fe", "country": "Argentina", "geoPoint": {"lat": -31.63333, "lon": -60.7}}, {"facility": "Research Site", "city": "Porto Alegre", "state": "Brasil", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Research Site", "city": "Rio de Janeiro", "state": "RJ", "country": "Brazil", "geoPoint": {"lat": -22.90278, "lon": -43.2075}}, {"facility": "Research Site", "city": "Santo Andre", "state": "SP", "country": "Brazil", "geoPoint": {"lat": -23.66389, "lon": -46.53833}}, {"facility": "Research Site", "city": "Sao Paulo", "state": "SP", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "Research Site", "city": "Barrio Los Yoses", "state": "San Jose", "country": "Costa Rica"}, {"facility": "Research Site", "city": "San Francisco de Dos Rios", "state": "San Jose", "country": "Costa Rica", "geoPoint": {"lat": 9.9078, "lon": -84.0563}}, {"facility": "Research Site", "city": "Bialystok", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Research Site", "city": "Bydgoszcz", "country": "Poland", "geoPoint": {"lat": 53.1235, "lon": 18.00762}}, {"facility": "Research Site", "city": "Gdalsk", "country": "Poland"}, {"facility": "Research Site", "city": "Kielce", "country": "Poland", "geoPoint": {"lat": 50.87033, "lon": 20.62752}}, {"facility": "Research Site", "city": "Krakow", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Research Site", "city": "Lublin", "country": "Poland", "geoPoint": {"lat": 51.25, "lon": 22.56667}}, {"facility": "Research Site", "city": "Poznal", "country": "Poland"}, {"facility": "Research Site", "city": "Szczecin", "country": "Poland", "geoPoint": {"lat": 53.42894, "lon": 14.55302}}, {"facility": "Research Site", "city": "Tarnow", "country": "Poland", "geoPoint": {"lat": 50.01381, "lon": 20.98698}}, {"facility": "Research Site", "city": "Turek", "country": "Poland", "geoPoint": {"lat": 52.01548, "lon": 18.50055}}, {"facility": "Research Site", "city": "Wroclaw", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "510 patients enrolled, 368 were allocated to treatment and 350 completed the study. First patient entered the study on 16 September 2008 and the last patient finished the study on 13 July 2009.", "groups": [{"id": "FG000", "title": "AZD1981 50 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 50 mg, twice daily"}, {"id": "FG001", "title": "AZD1981 400 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 400 mg, twice daily"}, {"id": "FG002", "title": "AZD1981 1000 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 1000 mg, twice daily"}, {"id": "FG003", "title": "Placebo", "description": "placebo oral tablet, twice daily"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "95"}, {"groupId": "FG001", "numSubjects": "90"}, {"groupId": "FG002", "numSubjects": "92"}, {"groupId": "FG003", "numSubjects": "91"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "92"}, {"groupId": "FG001", "numSubjects": "87"}, {"groupId": "FG002", "numSubjects": "86"}, {"groupId": "FG003", "numSubjects": "85"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "4"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Palm stopped to work", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "AZD1981 50 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 50 mg, twice daily"}, {"id": "BG001", "title": "AZD1981 400 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 400 mg, twice daily"}, {"id": "BG002", "title": "AZD1981 1000 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 1000 mg, twice daily"}, {"id": "BG003", "title": "Placebo", "description": "placebo oral tablet, twice daily"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "95"}, {"groupId": "BG001", "value": "90"}, {"groupId": "BG002", "value": "92"}, {"groupId": "BG003", "value": "91"}, {"groupId": "BG004", "value": "368"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "43.3", "lowerLimit": "18", "upperLimit": "76"}, {"groupId": "BG001", "value": "43", "lowerLimit": "18", "upperLimit": "79"}, {"groupId": "BG002", "value": "43.5", "lowerLimit": "18", "upperLimit": "77"}, {"groupId": "BG003", "value": "45.7", "lowerLimit": "18", "upperLimit": "77"}, {"groupId": "BG004", "value": "44.35", "lowerLimit": "18", "upperLimit": "79"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "34"}, {"groupId": "BG003", "value": "33"}, {"groupId": "BG004", "value": "113"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "68"}, {"groupId": "BG001", "value": "71"}, {"groupId": "BG002", "value": "58"}, {"groupId": "BG003", "value": "58"}, {"groupId": "BG004", "value": "255"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Morning Peak Expiratory Flow (mPEF)", "description": "Mean mPEF during the treatment period (mean of the last 2 weeks of the treatment period)", "populationDescription": "The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/min", "timeFrame": "Week 4", "groups": [{"id": "OG000", "title": "AZD1981 50 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 50 mg, twice daily"}, {"id": "OG001", "title": "AZD1981 400 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 400 mg, twice daily"}, {"id": "OG002", "title": "AZD1981 1000 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 1000 mg, twice daily"}, {"id": "OG003", "title": "Placebo", "description": "placebo oral tablet, twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "89"}, {"groupId": "OG002", "value": "92"}, {"groupId": "OG003", "value": "90"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "346.42", "spread": "132.70", "lowerLimit": "-245", "upperLimit": "334"}, {"groupId": "OG001", "value": "362.54", "spread": "134.69", "lowerLimit": "-131", "upperLimit": "213"}, {"groupId": "OG002", "value": "352.87", "spread": "124.22", "lowerLimit": "-158", "upperLimit": "219"}, {"groupId": "OG003", "value": "329.75", "spread": "140.14", "lowerLimit": "-283", "upperLimit": "158"}]}]}]}, {"type": "SECONDARY", "title": "Evening Peak Expiratory Flow (ePEF)", "description": "Mean ePEF during the treatment period (mean of the last 2 weeks of the treatment period)", "populationDescription": "The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/min", "timeFrame": "Week 4", "groups": [{"id": "OG000", "title": "AZD1981 50 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 50 mg, twice daily"}, {"id": "OG001", "title": "AZD1981 400 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 400 mg, twice daily"}, {"id": "OG002", "title": "AZD1981 1000 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 1000 mg, twice daily"}, {"id": "OG003", "title": "Placebo", "description": "placebo oral tablet, twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "89"}, {"groupId": "OG002", "value": "92"}, {"groupId": "OG003", "value": "91"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "359.83", "spread": "129.23", "lowerLimit": "-192", "upperLimit": "315"}, {"groupId": "OG001", "value": "378.98", "spread": "134.54", "lowerLimit": "-179", "upperLimit": "262"}, {"groupId": "OG002", "value": "368.70", "spread": "124.08", "lowerLimit": "-149", "upperLimit": "225"}, {"groupId": "OG003", "value": "348.87", "spread": "142.92", "lowerLimit": "-202", "upperLimit": "197"}]}]}]}, {"type": "SECONDARY", "title": "Morning Forced Expiratory Volume in 1 Second (mFEV1)", "description": "Mean mFEV1 during the treatment period (mean of the last 2 weeks of the treatment period)", "populationDescription": "The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L", "timeFrame": "Week 4", "groups": [{"id": "OG000", "title": "AZD1981 50 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 50 mg, twice daily"}, {"id": "OG001", "title": "AZD1981 400 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 400 mg, twice daily"}, {"id": "OG002", "title": "AZD1981 1000 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 1000 mg, twice daily"}, {"id": "OG003", "title": "Placebo", "description": "placebo oral tablet, twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "63"}, {"groupId": "OG002", "value": "71"}, {"groupId": "OG003", "value": "71"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.45", "spread": "0.99", "lowerLimit": "-1.24", "upperLimit": "1.80"}, {"groupId": "OG001", "value": "2.65", "spread": "1.03", "lowerLimit": "-1.41", "upperLimit": "1.04"}, {"groupId": "OG002", "value": "2.53", "spread": "0.97", "lowerLimit": "-0.503", "upperLimit": "0.843"}, {"groupId": "OG003", "value": "2.31", "spread": "1.05", "lowerLimit": "-2.21", "upperLimit": "1.12"}]}]}]}, {"type": "SECONDARY", "title": "Evening Forced Expiratory Volume in 1 Second (eFEV1)", "description": "Mean eFEV1 during the treatment period (mean of the last 2 weeks of the treatment period)", "populationDescription": "The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L", "timeFrame": "Week 4", "groups": [{"id": "OG000", "title": "AZD1981 50 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 50 mg, twice daily"}, {"id": "OG001", "title": "AZD1981 400 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 400 mg, twice daily"}, {"id": "OG002", "title": "AZD1981 1000 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 1000 mg, twice daily"}, {"id": "OG003", "title": "Placebo", "description": "placebo oral tablet, twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "66"}, {"groupId": "OG002", "value": "73"}, {"groupId": "OG003", "value": "72"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.47", "spread": "0.95", "lowerLimit": "-0.834", "upperLimit": "1.17"}, {"groupId": "OG001", "value": "2.72", "spread": "1.02", "lowerLimit": "-1.56", "upperLimit": "1.20"}, {"groupId": "OG002", "value": "2.63", "spread": "0.98", "lowerLimit": "-0.765", "upperLimit": "2.03"}, {"groupId": "OG003", "value": "2.43", "spread": "1.06", "lowerLimit": "-1.46", "upperLimit": "1.66"}]}]}]}, {"type": "SECONDARY", "title": "Total Use of Reliever", "description": "Mean total reliever use during the treatment period (mean of the last 2 weeks of the treatment period)", "populationDescription": "The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Number of inhalations per day", "timeFrame": "Week 4", "groups": [{"id": "OG000", "title": "AZD1981 50 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 50 mg, twice daily"}, {"id": "OG001", "title": "AZD1981 400 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 400 mg, twice daily"}, {"id": "OG002", "title": "AZD1981 1000 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 1000 mg, twice daily"}, {"id": "OG003", "title": "Placebo", "description": "placebo oral tablet, twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "90"}, {"groupId": "OG002", "value": "92"}, {"groupId": "OG003", "value": "91"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.870", "spread": "2.475", "lowerLimit": "-4.80", "upperLimit": "5.34"}, {"groupId": "OG001", "value": "2.640", "spread": "2.303", "lowerLimit": "-6.36", "upperLimit": "6.59"}, {"groupId": "OG002", "value": "2.569", "spread": "2.210", "lowerLimit": "-8.30", "upperLimit": "3.23"}, {"groupId": "OG003", "value": "2.855", "spread": "2.430", "lowerLimit": "-6.79", "upperLimit": "2.84"}]}]}]}, {"type": "SECONDARY", "title": "Night-time Asthma Symptom Score", "description": "Mean night-time asthma symptom score during the treatment period (mean of the last 2 weeks of the treatment period). Scores range from 0 (none) to 3 (bad).", "populationDescription": "The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Week 4", "groups": [{"id": "OG000", "title": "AZD1981 50 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 50 mg, twice daily"}, {"id": "OG001", "title": "AZD1981 400 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 400 mg, twice daily"}, {"id": "OG002", "title": "AZD1981 1000 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 1000 mg, twice daily"}, {"id": "OG003", "title": "Placebo", "description": "placebo oral tablet, twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "90"}, {"groupId": "OG002", "value": "92"}, {"groupId": "OG003", "value": "91"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.998", "spread": "0.633", "lowerLimit": "-2.80", "upperLimit": "0.733"}, {"groupId": "OG001", "value": "0.881", "spread": "0.543", "lowerLimit": "-1.36", "upperLimit": "0.786"}, {"groupId": "OG002", "value": "0.912", "spread": "0.594", "lowerLimit": "-1.83", "upperLimit": "0.655"}, {"groupId": "OG003", "value": "1.008", "spread": "0.614", "lowerLimit": "-2.12", "upperLimit": "0.714"}]}]}]}, {"type": "SECONDARY", "title": "Day-time Asthma Symptom Score", "description": "Mean day-time asthma symptom score during the treatment period (mean of the last 2 weeks of the treatment period). Scores range from 0 (none) to 3 (bad).", "populationDescription": "The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Week 4", "groups": [{"id": "OG000", "title": "AZD1981 50 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 50 mg, twice daily"}, {"id": "OG001", "title": "AZD1981 400 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 400 mg, twice daily"}, {"id": "OG002", "title": "AZD1981 1000 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 1000 mg, twice daily"}, {"id": "OG003", "title": "Placebo", "description": "placebo oral tablet, twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "90"}, {"groupId": "OG002", "value": "92"}, {"groupId": "OG003", "value": "91"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.037", "spread": "0.609", "lowerLimit": "-2.80", "upperLimit": "0.850"}, {"groupId": "OG001", "value": "0.933", "spread": "0.556", "lowerLimit": "-1.00", "upperLimit": "1.04"}, {"groupId": "OG002", "value": "0.995", "spread": "0.552", "lowerLimit": "-2.20", "upperLimit": "1.25"}, {"groupId": "OG003", "value": "1.105", "spread": "0.645", "lowerLimit": "-2.00", "upperLimit": "1.62"}]}]}]}, {"type": "SECONDARY", "title": "Awakenings", "description": "Mean percentage of awakenings due to asthma symptoms during the treatment period (mean of the last 2 weeks of the treatment period)", "populationDescription": "The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of days", "timeFrame": "Week 4", "groups": [{"id": "OG000", "title": "AZD1981 50 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 50 mg, twice daily"}, {"id": "OG001", "title": "AZD1981 400 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 400 mg, twice daily"}, {"id": "OG002", "title": "AZD1981 1000 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 1000 mg, twice daily"}, {"id": "OG003", "title": "Placebo", "description": "placebo oral tablet, twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "90"}, {"groupId": "OG002", "value": "92"}, {"groupId": "OG003", "value": "91"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "38.59", "spread": "40.25", "lowerLimit": "-100", "upperLimit": "44.4"}, {"groupId": "OG001", "value": "33.18", "spread": "38.93", "lowerLimit": "-84.6", "upperLimit": "100"}, {"groupId": "OG002", "value": "33.34", "spread": "37.68", "lowerLimit": "-92.3", "upperLimit": "60"}, {"groupId": "OG003", "value": "37.32", "spread": "39.51", "lowerLimit": "-100", "upperLimit": "58.6"}]}]}]}, {"type": "SECONDARY", "title": "Asthma Control Day", "description": "Mean percentage of asthma control days during the treatment period (mean of the last 2 weeks of the treatment period). An asthma control day is defined as a symptom-free day with no use of reliever medication during day and night. A symptom-free day is defined as a day and a night with no asthma symptoms and a day and night with no awakenings due to asthma symptoms.", "populationDescription": "The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of days", "timeFrame": "Week 4", "groups": [{"id": "OG000", "title": "AZD1981 50 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 50 mg, twice daily"}, {"id": "OG001", "title": "AZD1981 400 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 400 mg, twice daily"}, {"id": "OG002", "title": "AZD1981 1000 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 1000 mg, twice daily"}, {"id": "OG003", "title": "Placebo", "description": "placebo oral tablet, twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "90"}, {"groupId": "OG002", "value": "92"}, {"groupId": "OG003", "value": "91"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.78", "spread": "25.79", "lowerLimit": "-12.5", "upperLimit": "100"}, {"groupId": "OG001", "value": "7.48", "spread": "20.71", "lowerLimit": "-20", "upperLimit": "100"}, {"groupId": "OG002", "value": "13.23", "spread": "26.24", "lowerLimit": "-38.3", "upperLimit": "100"}, {"groupId": "OG003", "value": "10.08", "spread": "22.36", "lowerLimit": "-1.67", "upperLimit": "100"}]}]}]}, {"type": "SECONDARY", "title": "Symptom Free Day", "description": "Mean percentage of symptom free days during the treatment period (mean of the last 2 weeks of the treatment period). A symptom-free day is defined as a day and a night with no asthma symptoms and a day and night with no awakenings due to asthma symptoms.", "populationDescription": "The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of days", "timeFrame": "Week 4", "groups": [{"id": "OG000", "title": "AZD1981 50 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 50 mg, twice daily"}, {"id": "OG001", "title": "AZD1981 400 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 400 mg, twice daily"}, {"id": "OG002", "title": "AZD1981 1000 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 1000 mg, twice daily"}, {"id": "OG003", "title": "Placebo", "description": "placebo oral tablet, twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "90"}, {"groupId": "OG002", "value": "92"}, {"groupId": "OG003", "value": "91"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "17.33", "spread": "32.16", "lowerLimit": "-49.2", "upperLimit": "100"}, {"groupId": "OG001", "value": "13.95", "spread": "28.35", "lowerLimit": "-52.3", "upperLimit": "100"}, {"groupId": "OG002", "value": "15.56", "spread": "28.51", "lowerLimit": "-72.3", "upperLimit": "100"}, {"groupId": "OG003", "value": "14.31", "spread": "26.28", "lowerLimit": "-23.8", "upperLimit": "100"}]}]}]}, {"type": "SECONDARY", "title": "Reliever Free Day", "description": "Mean percentage of reliever free days during the treatment period (mean of the last 2 weeks of the treatment period). A reliever free day is defined as a day and a night with no use of as-needed medication.", "populationDescription": "The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of days", "timeFrame": "Week 4", "groups": [{"id": "OG000", "title": "AZD1981 50 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 50 mg, twice daily"}, {"id": "OG001", "title": "AZD1981 400 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 400 mg, twice daily"}, {"id": "OG002", "title": "AZD1981 1000 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 1000 mg, twice daily"}, {"id": "OG003", "title": "Placebo", "description": "placebo oral tablet, twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "90"}, {"groupId": "OG002", "value": "92"}, {"groupId": "OG003", "value": "91"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "22.59", "spread": "34.57", "lowerLimit": "-16.9", "upperLimit": "100"}, {"groupId": "OG001", "value": "20.60", "spread": "32.01", "lowerLimit": "-30.0", "upperLimit": "100"}, {"groupId": "OG002", "value": "24.13", "spread": "32.12", "lowerLimit": "-50.0", "upperLimit": "100"}, {"groupId": "OG003", "value": "20.94", "spread": "32.97", "lowerLimit": "-23.6", "upperLimit": "100"}]}]}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume in 1 Second (FEV1) at the Clinic", "description": "Mean FEV1 during the treatment period (mean value at Week 4)", "populationDescription": "The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L", "timeFrame": "Week 4", "groups": [{"id": "OG000", "title": "AZD1981 50 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 50 mg, twice daily"}, {"id": "OG001", "title": "AZD1981 400 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 400 mg, twice daily"}, {"id": "OG002", "title": "AZD1981 1000 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 1000 mg, twice daily"}, {"id": "OG003", "title": "Placebo", "description": "placebo oral tablet, twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "93"}, {"groupId": "OG001", "value": "90"}, {"groupId": "OG002", "value": "92"}, {"groupId": "OG003", "value": "88"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.653", "spread": "1.051", "lowerLimit": "-0.760", "upperLimit": "2.02"}, {"groupId": "OG001", "value": "2.739", "spread": "1.028", "lowerLimit": "-0.730", "upperLimit": "2.16"}, {"groupId": "OG002", "value": "2.628", "spread": "1.057", "lowerLimit": "-2.46", "upperLimit": "2.04"}, {"groupId": "OG003", "value": "2.400", "spread": "0.945", "lowerLimit": "-0.740", "upperLimit": "1.26"}]}]}]}, {"type": "SECONDARY", "title": "Forced Vital Capacity (FVC) at the Clinic", "description": "Mean FVC during the treatment period (mean value at Week 4)", "populationDescription": "The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L", "timeFrame": "Week 4", "groups": [{"id": "OG000", "title": "AZD1981 50 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 50 mg, twice daily"}, {"id": "OG001", "title": "AZD1981 400 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 400 mg, twice daily"}, {"id": "OG002", "title": "AZD1981 1000 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 1000 mg, twice daily"}, {"id": "OG003", "title": "Placebo", "description": "placebo oral tablet, twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "93"}, {"groupId": "OG001", "value": "90"}, {"groupId": "OG002", "value": "92"}, {"groupId": "OG003", "value": "88"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.704", "spread": "1.268", "lowerLimit": "-1.48", "upperLimit": "2.21"}, {"groupId": "OG001", "value": "3.892", "spread": "1.295", "lowerLimit": "-0.980", "upperLimit": "2.30"}, {"groupId": "OG002", "value": "3.546", "spread": "1.257", "lowerLimit": "-1.03", "upperLimit": "2.68"}, {"groupId": "OG003", "value": "3.563", "spread": "1.215", "lowerLimit": "-0.990", "upperLimit": "2.02"}]}]}]}, {"type": "SECONDARY", "title": "Asthma Control Questionnaire 5 Items (ACQ5)", "description": "Mean ACQ5 score during the treatment period (mean value at Week 4). Scores range from 0 (good) to 6 (poor control).", "populationDescription": "The efficacy analysis is based on 368 total randomized patients with available data. However, not all patients will have valid, non-missing values for a given outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Full Range", "unitOfMeasure": "Scores on a scale", "timeFrame": "Week 4", "groups": [{"id": "OG000", "title": "AZD1981 50 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 50 mg, twice daily"}, {"id": "OG001", "title": "AZD1981 400 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 400 mg, twice daily"}, {"id": "OG002", "title": "AZD1981 1000 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 1000 mg, twice daily"}, {"id": "OG003", "title": "Placebo", "description": "placebo oral tablet, twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "89"}, {"groupId": "OG002", "value": "86"}, {"groupId": "OG003", "value": "85"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.69", "spread": "-2.40", "lowerLimit": "0", "upperLimit": "4.00"}, {"groupId": "OG001", "value": "1.58", "spread": "-2.40", "lowerLimit": "0", "upperLimit": "3.80"}, {"groupId": "OG002", "value": "1.64", "spread": "-3.20", "lowerLimit": "0", "upperLimit": "4.60"}, {"groupId": "OG003", "value": "1.91", "spread": "-2.60", "lowerLimit": "0", "upperLimit": "4.20"}]}]}]}, {"type": "SECONDARY", "title": "Adverse Event (AE)", "description": "Number of patients reporting at least one event", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "AZD1981 50 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 50 mg, twice daily"}, {"id": "OG001", "title": "AZD1981 400 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 400 mg, twice daily"}, {"id": "OG002", "title": "AZD1981 1000 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 1000 mg, twice daily"}, {"id": "OG003", "title": "Placebo", "description": "placebo oral tablet, twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "90"}, {"groupId": "OG002", "value": "92"}, {"groupId": "OG003", "value": "91"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "33"}, {"groupId": "OG003", "value": "24"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "eventGroups": [{"id": "EG000", "title": "AZD1981 50 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 50 mg, twice daily", "seriousNumAffected": 0, "seriousNumAtRisk": 95, "otherNumAffected": 5, "otherNumAtRisk": 95}, {"id": "EG001", "title": "AZD1981 400 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 400 mg, twice daily", "seriousNumAffected": 0, "seriousNumAtRisk": 90, "otherNumAffected": 6, "otherNumAtRisk": 90}, {"id": "EG002", "title": "AZD1981 1000 mg Twice Daily (Bid)", "description": "AZD1981 oral tablet 1000 mg, twice daily", "seriousNumAffected": 1, "seriousNumAtRisk": 92, "otherNumAffected": 11, "otherNumAtRisk": 92}, {"id": "EG003", "title": "Placebo", "description": "placebo oral tablet, twice daily", "seriousNumAffected": 1, "seriousNumAtRisk": 91, "otherNumAffected": 7, "otherNumAtRisk": 91}], "seriousEvents": [{"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 91}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 95}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 91}]}], "otherEvents": [{"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 95}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 92}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 91}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 95}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 90}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 92}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 91}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 95}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 92}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 91}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "LTE60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Alison Holt", "organization": "AstraZeneca", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}}, "hasResults": true}